Edge Therapeutics Raises $72.5 Million Through Successive Series C-1 and C-2 Financings

BERKELEY HEIGHTS, N.J.–(BUSINESS WIRE)– Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for acute, life-threatening neurological conditions, today announced that it has raised approximately $72.5 million in gross proceeds from two recently completed private financing rounds. The most recent round, a $56 million Series C-2 financing, was completed in April 2015 and was led by Venrock with participation of Sofinnova Ventures, Janus Capital Management LLC, funds managed by Franklin Advisers, Inc., New Leaf Venture Partners and BioMed Ventures. The earlier round, a $16.5 million Series C-1 financing, was completed in December 2014 and included investments by a number of high net worth individuals, family offices and private foundations.

This entry was posted in Recent Developments. Bookmark the permalink.
Read Full Article »